Attomarker To Lead New Medical Intervention to Explore Monoclonal Antibody Treatment for Long COVID
EXETER, UK – 4 April 2025 – Attomarker, a leader in rapid diagnostic technology, today announced its plans for a new study evaluating the use of AstraZeneca’s monoclonal antibody, Sopavibart (Kavigale), as a potential treatment for long COVID patients. Long COVID...
International Long COVID Awareness Day 2025
International Long COVID Awareness Day 2025 Five Years On, Long COVID Patients Are Still Being Left Behind On 15th March we mark five years since the start of the pandemic and with it, International Long COVID Awareness Day. While COVID-19 may have faded from...
Treating Long Covid: The Persistent Virus Hypothesis
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: Visit our clinics Elimination of a SARS-CoV-2 infection requires both antibody and T cells for complete clearance of the coronavirus from the localised infection site. Systemic...
Attomarker has been selected as one of the companies by Innovate UK
Attomarker has been selected as one of the companies by Innovate UK for the following category: GBIP in Hyderabad and Bangalore, India - Antimicrobial Resistance, diagnostics and therapeutics Why India? India has recognised the importance of AMR, and the Indian...
Attomarker is Revolutionising Diagnostic Technology and the Potential of Big Data
We are working with partners to enable early medical intervention for longer, healthier lives for humans and animals. Attomarker Ltd is offering an Advanced Subscription Agreement funding round to support product development, regulatory and roll out. A full set...
Treating Long Covid: The Persistent Virus Hypothesis
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: longcovid@re-cognitionhealth.comElimination of a SARS-CoV-2 infection requires both antibody and T cells for complete clearance of the coronavirus from the localised infection site. Systemic...
Long Covid – can we weaken its grip?
#LongCovid is now affecting over 2 million people in the UK, a "mass disabling event" harming health and livelihoods. In the US, where it is reported over 20 million are afflicted with the condition, Long Covid is being described as the “next public health disaster”...
Back to School: COVID predicted to cause further disruption to education
Schools have returned About a month ago, schools returned for the 2022/23 academic year. This will expose many teachers and students to viruses brought home from summer holidays and socialising with family and friends. These viruses include the new Omicron variants of...
Science Briefing: COVID-19 Antibody Immunity Testing – Interpreting the Results
Attomarker has developed a COVID-19 Antibody Immunity test which is fully CE marked and is fully quantitative referenced to the NIST standard human antibody.The test is a fully quantitative immunoassay calibrated against the conserved S2 regions of the spike protein,...
Science Briefing: COVID-19 Antibody Immunity Testing vs. T Cell Immunity
What is Immunity? Immunity is a complex process with both innate and adaptive immunity. The adaptive arm of the immune system comprises both antibody responses and T cell responses. Most recently, the role of T cells and antibodies has become an important point of...
Science Briefing: Quantitative Antibody Testing against the NIST Standard
The Attomarker COVID-19 Antibody Immunity Test is a fully quantitative immunoassay calibrated against the conserved S2 regions of the spike protein, omicron spike protein, nucleocapsid and receptor binding domain proteins with recombinant antibodies calibrated against...
What is Long COVID?
What is Long Covid? Long Covid, also known as long-haul covid or post-acute COVID syndrome (PACS), is being increasingly discussed in the media as cases persist in the United Kingdom. Both the NHS and the CDC identify it as COVID-19 symptoms that continue for longer...
